Scalper1 News
New FDA documents released Friday said patients on popular AstraZeneca (AZN) diabetes drug Onglyza show an increased risk of death. AstraZeneca’s stock fell 2% in early trading. The briefing documents came out ahead of an advisory committee panel convening Tuesday to evaluate the safety of Onglyza (generically called saxagliptin) and a similar drug, Takeda’s Nesina, in light of two cardiovascular (CV) outcomes trials called Savor and Examine, Scalper1 News
Scalper1 News